Free Trial

Waldencast PLC (NASDAQ:WALD) Receives Consensus Rating of "Moderate Buy" from Analysts

Waldencast logo with Consumer Staples background

Waldencast PLC (NASDAQ:WALD - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $5.11.

A number of research firms have recently commented on WALD. Wall Street Zen lowered shares of Waldencast from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Canaccord Genuity Group dropped their price target on shares of Waldencast from $6.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Alliance Global Partners reissued a "buy" rating on shares of Waldencast in a research report on Thursday, May 15th. Telsey Advisory Group dropped their price target on shares of Waldencast from $5.00 to $4.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Finally, DA Davidson reaffirmed a "buy" rating and set a $7.50 target price on shares of Waldencast in a research report on Wednesday, March 19th.

Check Out Our Latest Report on Waldencast

Waldencast Trading Down 3.4%

Shares of NASDAQ:WALD traded down $0.09 during trading on Friday, reaching $2.58. The stock had a trading volume of 111,425 shares, compared to its average volume of 132,932. Waldencast has a 52 week low of $1.98 and a 52 week high of $4.74. The company has a current ratio of 1.35, a quick ratio of 0.66 and a debt-to-equity ratio of 0.21. The stock has a fifty day simple moving average of $2.49 and a two-hundred day simple moving average of $2.92.

Hedge Funds Weigh In On Waldencast

Institutional investors and hedge funds have recently bought and sold shares of the stock. Stonebrook Private Inc. bought a new stake in Waldencast in the 4th quarter valued at $48,000. Ethic Inc. bought a new stake in Waldencast in the 4th quarter valued at $56,000. Wells Fargo & Company MN increased its holdings in Waldencast by 29.9% in the 4th quarter. Wells Fargo & Company MN now owns 14,571 shares of the company's stock valued at $59,000 after buying an additional 3,358 shares during the period. XTX Topco Ltd bought a new stake in Waldencast in the 4th quarter valued at $70,000. Finally, Jane Street Group LLC bought a new stake in Waldencast in the 1st quarter valued at $77,000. Institutional investors own 41.97% of the company's stock.

Waldencast Company Profile

(Get Free Report

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.

Featured Stories

Analyst Recommendations for Waldencast (NASDAQ:WALD)

Should You Invest $1,000 in Waldencast Right Now?

Before you consider Waldencast, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waldencast wasn't on the list.

While Waldencast currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines